N1-((1S,2R,4S)-2-amino-4-(dimethylcarbamoyl)cyclohexyl)-N2-(5-chloropyridin-2-yl)oxalamide hydrochloride

Catalog No. :
ACGCFA288
CAS No. :
482375-18-8
Molecular Formula :
C16H23Cl2N5O3
Molecular Weight :
404.30

IUPAC Name:N1-((1S,2R,4S)-2-amino-4-(dimethylcarbamoyl)cyclohexyl)-N2-(5-chloropyridin-2-yl)oxalamide hydrochloride

N1-((1S,2R,4S)-2-amino-4-(dimethylcarbamoyl)cyclohexyl)-N2-(5-chloropyridin-2-yl)oxalamide hydrochloride structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameN1-((1S,2R,4S)-2-amino-4-(dimethylcarbamoyl)cyclohexyl)-N2-(5-chloropyridin-2-yl)oxalamide hydrochloride
IUPAC NameN1-((1S,2R,4S)-2-amino-4-(dimethylcarbamoyl)cyclohexyl)-N2-(5-chloropyridin-2-yl)oxalamide hydrochloride
Molecular FormulaC16H23Cl2N5O3
Molecular Weight404.30
SMILESO=C(N[C@@H]1[C@H](N)C[C@@H](C(N(C)C)=O)CC1)C(NC2=NC=C(Cl)C=C2)=O.[H]Cl
InChI KeySCFBXGHGMBMEPI-CRGLIXAISA-N
SynonymN1-{(1S,2R,4S)-2-amino-4-[(dimethylamino)carbonyl]-cyclohexyl}-N2-(5-chloropyridin-2-yl)ethanediamide hydrochloride;EthanediaMide iMpurity F hcl;N1-((1S,2R,4S)-2-amino-4-(dimethylcarbamoyl)cyclohexyl)-N2-(5-chloropyridin-2-yl)oxalamide hydrochloride;Edoxaban Impurity: N1-((1S,2R,4S)-2-amino-4-(dimethylcarbamoyl)cyclohexyl)-N2-(5-chloropyridin-2-yl)oxalamide hydrochloride
CAS No.482375-18-8

Synthetic Route by SureRoute

1. ACGCFA288 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACELYT246 route compound structure diagram
    ACELYT246480452-36-6 In Stock
  2. Then
  3. ACGCFA288 route product structure diagram
    ACGCFA288482375-18-8
Inquiry

2. ACGCFA288 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACGCFA288 route product structure diagram
    ACGCFA288482375-18-8
Inquiry

Comments (0)